This personalized approach holds great potential for optimizing treatment strategies and improving patient outcomes in breast cancer therapy [6, 7]. siRNA-CD73 is a novel therapeutic approach that utilizes siRNA to target and inhibit the expression of CD73 in converting extracellular adenosine monophosphate (AMP) to adenosine, which has immunosuppressive effects and promotes tumor growth. The gene discussed is NT5E; the disease is breast carcinoma.